Founded in Raleigh, United States, FLAG Therapeutics is an early-stage oncology company dedicated to developing innovative therapies for difficult-to-treat cancers. The company's core mission is to advance cancer treatment through its proprietary Anti-angiogenic/Anti-tubulin (AA/AT) and Folate-target Anti-cancer (FTAC) platforms. FLAG Therapeutics' lead candidate, FLAG-003, targets glioblastoma multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG), with plans to enter Phase 1 clinical development soon.
FLAG Therapeutics has garnered attention from notable investors and industry experts due to its promising drug discovery platforms. The company’s significant achievements include the development of its lead candidate, FLAG-003, which addresses critical unmet needs in oncology. By focusing on innovative small molecule therapeutics, FLAG Therapeutics aims to make a substantial impact on the treatment landscape for some of the most challenging cancers.
